## UNITED STATES PATENT AND TRADEMARK OFFICE

Re:

Application of:

Ronald M. BURCH, et al.

Serial No.:

Not yet assigned

Filed:

Herewith

For:

ANALGESIC COMBINATION OF OXYCODONE

AND SC-58215

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents and Trademarks Washington, D.C. 20231

January 25, 2002

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying PTO-1449 Form for consideration by the Examiner in connection with the examination of the above-noted patent application.

In accordance with 37 C.F.R. § 1.98(d), copies of the listed references are not enclosed as the references cited in the attached Form PTO-1449 have been previously submitted to the PTO or were cited by the Examiner during prosecution of parent application, U.S. Serial No. 09/154,354, entitled, "Analgesic Combination Of Oxycodone And Rofecoxib."

The Examiner's attention is directed to the following copending related applications:

U.S. Serial No. (Not yet known), filed, December 27, 2001, entitled "Analgesic Combination of Oxycodone and Celecoxib",

1

200.1079.CON6

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic

Combination of Oxycodone and 6-MNA",

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic

Combination of Oxycodone and Nabumetone",

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic

Combination of Oxycodone and Nimesulide",

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic

Combination of Oxycodone and Meloxicam" and

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic

Combination of Oxycodone and T-614".

It is respectfully requested that the references cited in the accompanying PTO-1449 Form

be considered and made of record. If any of the publications listed thereon are missing, the

Examiner is requested to contact the undersigned so that a copy can be promptly forwarded.

This information disclosure statement is being filed together with the filing of the

application and before the mailing date of a first Office Action on the merits. Therefore, under

37 C.F.R. § 1.97 (b), it is believed no fee is required. If it is determined that any fees are due at

this time, the Assistant Commissioner is hereby authorized to charge said fees to Deposit

Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By.

Robert J. Paradiso

Reg. No. 41,240

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018

(212) 736-1940

2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO.: 200.1079CON6 SERIAL NO.: Not yet known PATENT AND TRADEMARK OFFICE (REV. 7-80) APPLICANT(S): Ronald M. BURCH, et al. LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) FILING DATE: Herewith GROUP: Not Yet Known **U.S. PATENT DOCUMENTS** \*EXAMINER **DOCUMENT NUMBER** DATE NAME CLASS **SUBCLASS** FILING DATE INITIAL IF APPROPRIATE AΑ 5 01/12/99 548 247 08/14/96 Talley 5 3 9 2 2 AB 8 6 01/26/99 514 270 07/02/99 Mayer, et al. AC 5 8 0 7 3 11/24/98 514 289 08/02/95 4 1 Mayer, et al. ΑD 5 8 9 9 02/09/99 514 282 07/07/97 б 4 R Mayer, et al. 5 8 9 01/19/99 334 07/11/97 ΑE 6 1 1 Dube, et al. 514 7 ΑF 5 8 9 4 3 08/04/98 Black, et al. 514 255 01/21/97 AG 5 6 0 4 6 0 02/18/97 Guay, et al. 514 605 11/04/93 5 ΑH 4 5 8 8 9 10/17/95 Singh, et al. 424 400 09/30/94 5 5 0 ΑI 1 6 8 3 05/14/96 Raffa 514 570 03/01/95 AJ 8 4 3 4 6 8 12/01/98 Burkoth, et al. 424 448 05//13/96 OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) ΑK Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX) By NSAIDS: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Pairet, et al., Inflammopharmacology 4; 61-70, (1996). ALDifferential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. European J. Pharm 355 pp 211-217, (1998). AM Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998). AN Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996) A0 Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. And Applied Skin Phys. 11:273-278, (1998). ΑP Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cartiona Hay and Jacqueline de Belleroche, Neuro Report 8, 1249-1251, (1997). ΑQ The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996). AR Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47:79-85, (1998). AS Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, Vol. 16, No. 2, pp. 181-206, (1996).

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

**EXAMINER** 

FORM PTO-1449 (REV. 7-80)							OF COMMERCE	ATTY. DOCKET N	O.: 200.1079CON6	SERIAL NO.: N	lot Yet Known			
	LIST OF P	RIOR ART CI	TED BY	APPLICA	NT			APPLICANT(S): R	Ronald M. BURCH, et al	I.				
	(Use si	everal sheets i	if necess	ary)				FILING DATE: Not	Yet Known	GROUP: Not Ye	t Known			
							U.S. PATENT DOC	CUMENTS						
*EXAMINER INITIAL		DOCUMEN	IT NUMB	JER			DATE	NAME	CLASS	SUBCLASS	SUBCLASS FILING DATE IF APPROPRIATE			
	BA						<del> </del>							
	ВВ	<del>                                     </del>				$\bot$								
	ВС						ļ							
	BD	<del>                                     </del>	<del> </del>	+		$\bot$	+	<u> </u>			<del> </del>			
	BE			+			+	<del></del> -		<u> </u>	<del> </del>			
	BF	-	_	1			<del> </del>	<del> </del>		T				
	BG	├	<del> </del>	$\dashv$				ļ						
·	ВН	<del>                                     </del>	+	+		-					<del></del>			
	Bi		+-	+	$\dashv$	-	1							
	BJ	$\vdash$	+	+		_					+			
-	BK	<u> </u>		11										
<u> </u>						F0	REIGN PATENT DO	DCUMENTS T		T				
		DOCUMEN	IT NUMB	ER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	10N		
	<u> </u>										YES	NO NO		
	BL				l_		<u> </u>							
··	<del></del>			0	THER PRIC	OR ART (In	cluding Author, Tit	tle, Date, Pertinent Pa	ages, Etc.)					
	ВМ	Cyclooxyge	enase in t	ne ygoloic	d disease, f	Raymond N	I. Dubois, et al., FA	ASEB J. Vol. 12 pp. 10	<u> 363-1073 (1998).</u>			•		
	BN	Pharmacolo Preferentia	ogy of Mi Il Inhibitic	eloxicam, on of COX	A new Non 2, G. Enge	ı-Steroidal Ilhardt, Brit	Anti-Inflammatory tish J. Rheumatolo	Drug With An Improv gy, 35 (supp 1):4-12,	red Safety Profile Thro (1996)	ugh				
	B0	<u>Cyclooxyge</u> John L. Wa	enase 1 C illace, et	ontribute: al. Gastro	s to Inflam enterology	matory Res , 115:101-	sponses in Rats an 109 (1998).	d Mice: Implications f	for Gastrointestinal To	xicity,				
	ВР	Distinct iso M. Pairet a	oforms (C and G. En	OX-1 and gelhardt, i	COX-2) of	cyclooxygi in. Pharma	enase: possible phy col. 10:1-15, (199	ysiological and therap 6).	peutic implications,			7.00		
	BQ	Involvemen Hidenobu K	<u>it of Pros</u> Cusuhara,	taglandin: et al. Pro	Produced staglanding	by Cycloo: s 55: 43-4!	xygenase-1 in Muri 9, (1998).	ine Viscernonociceptio	on Induced by Phenylqu	<u>iinone,</u>				
	BR	Effect of Control in Rats. D.	OX-1 and Dirig, et	J COX-2 Ir	nhibition on Irmacol. Ar	Induction	and Maintenance o	of Carrageenan Evoker Vol. 285, No. 3, pp 1	d Thermal Hyperalgesi 1031-1038.	<u>a</u>				
EXAMINER									DATE CONSIDERED					
*EXAMINER: Initia	al if referen	ce considered	whethe	r or not ci	tation is in	conforman	nce with MPEP 600	Orang line through a	citation if not in confor					

FORM PTO-1449 (REV. 7-80)									OF COMMERCE EMARK OFFICE	ATTY. DOCKET NO 200.1079CON6	ı.:	SERIAL NO.: N	ot Yet Knownd	
L	IST OF PE	RIOR AF				NT				APPLICANT(S): Ro	nald M. BURCH, et a	1.		
										FILING DATE: Not	Yet Known	GROUP: Not	Yet Known	
						-		ι	J.S. PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOC	UMENT	NUMBE	R		_		DATE	NAME	CLASS	SUBCLASS	IATE	
	CA													
	СВ						<u> </u>							
	СС		ļ	<u> </u>	ļ		_							
	CO											ļ		
		,						FOF	REIGN PATENT D	OCUMENTS		1		
		DOC	UMENT	NUMBE	R				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	NO
	CE	9	9	0	7	4	1	3	2/18/99	wo				
	CF	9	9	3	2	1	1	9	7/1/99	wo_				
	CG													
	СН													
	CI								ļ					
	C1									<u></u>				
						OTHER	PRIOR .	ART (In	cluding Author, Ti	tle, Date, Pertinent Pa	ges, Etc.)			
	СК	Effec	t of me	loxicam	on post	operativ	e pain a	fter ab	dominal hysterect	omy, J.P. Thompson e	t al. British Journal o	f Anaesthesia 84 (2	2) 151-4 (2000).	
	CL	(5)	thecal c		genase	inhibitor	adminis	stration	attenuates morph	nine antinociceptive tol	erance in rats. C.S.	Wong et al., British	Journal of Anaes	thesia 85
	СМ	Cycle	oxygen	ase inhil	bitors in	ncrease	morphir	e effec	ts on mesolimbic	dopamine neurons, M.	Melis, et al. Eur. J. P	harmacology 387 (	1) R1-R3 (2000).	
	CN		rgistic a 82 (1) 6			ects of :	spinal m	orphine	with ketorolac ar	nd selective COX-1 an	d COX -2 inhibitors in	n nerve-injured rats,	J.M. Lashbrook,	et al.
	CO		ncemen nal of Pl						ptic transmission	by cyclo-oxygenase in	hibitors in rat periaqu	eductal grey neuro	nes, Vaughn et al.	British
EXAMINER										DATE CONSIDEREI	)			
*EXAMINER: Initia				whether	or not i	citation	is in cor	nforman	ce with MPEP 60	9; Draw line through c	itation if not in confo	ormance and not co	nsidered. Include	copy of this

FORM PTO-1449 (REV. 7-80)									OF COMMERCE EMARK OFFICE	ATTY. DOCKET NO.: 2	200.10 <b>79CON6</b>	SERIAL NO.: Not Yet Known			
	IST OF P	RIOR AI	RT CITE	D BY A	PPLICA	ANT				APPLICANT(S): Ronal	d M. BURCH, et al				
	(Use s	everal si	neets if	necessa	iry)					FILING DATE: Not Yet	Known	GROUP: Not Yet Known			
U.S. PATENT DO										UMENTS					
*EXAMINER INITIAL		DOC	UMENT	NUMB	ER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIA	iTE .	
	DA	5	4	7	4	9	9	5	12/12/95	Ducharme et al.	514	241	01/10/94		
	DB	5	6	9	1	3	7	4	11/25/97	Black et al.	514	473	05/18/95		
	DC														
	DD														
	DE														
	DF														
	DG														
	DH														
	DI														
	DJ														
	DK														
									REIGN PATENT D	OCUMENTS	•				
11		DOC	UMENT	NUMBI	ER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	V	
													YES	NO	
	DL														
	DM														
	DN														
	DO														
	DP														
			<del></del>	<u> </u>		OTHER	PRIOR	ART (In	cluding Author, Ti	tle, Date, Pertinent Pages	, Etc.)	•	•	•	
	DQ														
	DR														
	DS														
EXAMINER		•	· · · · · ·							DATE CONSIDERED					
*EXAMINER: Initia	al if refere	nce cons	sidered,	whethe	r or not	citation	is in co	nforman	ice with MPEP 60	9; Draw line through citat	tion if not in confo	rmance and not cons	sidered. Include c	opy of this	

FORM PTO-1449 REV. 7-80)	DATEST AND TRADESTADY OFFICE										ATTY. DOCKET NO.: 200.1079CON6   SERIAL NO.: Not Yet Known				
ι	IST OF PE	IOR AR	T CITEI	BY AF	PLICA	NT				APPLICANT(S): Ronald M. BURCH, et al.					
	(Use se	veral she	eets if n	ecessar	y)					FILING DATE: Not Yet	Known	GROUP: Not Yet Known			
								U.	S. PATENT DOC	UMENTS					
EXAMINER NITIAL		DOCU	IMENT	NUMBE	R				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIA	ATE	
	EA	3	8	0	0	0	4	1	03/26/74	Miller, et al.	424	273	03/02/71		
	EB	4	3	2	2	4	2	7	03/30/82	Buyinski, et al.	424	260	04/16/81		
	EC	4	3	3	8	3	2	4	06/06/82	Gardocki	424	266	03/17/81		
	ED	4	4	0	4	2	1	0	09/13/83	Schmidt	424	260	06/30/82		
	EE	4	4	0	7	8	0	4	10/04/83	Schmidt	424	260	06/30/82		
	EF	4	4	0	7	8	0	5	10/04/83	Schmidt	424	260	06/30/82		
	EG	4	4	6	4	3	7	6	08/07/84	Sunshine, et al.	424	253	10/11/83		
	EH	4	4	8	6	4	3	6	12/04/84	Sunshine, et al.	424	253	03/11/83		
	Ei	4	4	8	9	0	8	0	12/18/84	Lomen	424	260	12/06/82		
								FOF	REIGN PATENT D	OCUMENTS					
		DOCUMENT NUMBER DATE								COUNTRY	CLASS	SUBCLASS	TRANSLATIO	IN	
		ŀ											YES	NO	
	EJ	2	0	2	3	3	4	9	02/18/91	Canada	A61K	31/44			
	EK	0	2	7	4	8	4_	5	07/20/88	EP (A1)	A61K	31/19		<u> </u>	
	EL	0	3	8	8	1	2	5	09/19/90	EP (A1)	A61K	31/485			
	*					OTHER	PRIOR	ART (In	cluding Author, T	itle, Date, Pertinent Pag	es, Etc.)				
	EM	Phar Rect	macokii tal Admi	netics ar	nd Drug on A. Ha	Input C	haracte t al. Arz	ristics fo	or a Diclotenac-C rsch./Drug Res. 4	odeine Phosphate Combi 6 (I) 57-63 (1996).	nation Following Or	al and	2		
	EN	Com Chro	onic Ost	of a Sta eo-arthr	andard I itis G.I	buprof <u>e</u> K. Vlok,	n Treatr et al. U	ment Re niv. Stel	gimen with a Nev lenbosch and Tyg	v <u>                                     </u>	Codeine Combinati rthopaedic Surg. p	ion in ip 3-6,			
	EO														
	EP														
	EQ														
	ER														
EXAMINER		•								DATE CONSIDERED					

form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO.: 200.1079CON6 SERIAL NO.: Not Yet Known (REV. 7-80) PATENT AND TRADEMARK OFFICE APPLICANT(S): Ronald M. BURCH, et al. LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) FILING DATE: Not Yet Known **GROUP: Not Yet Known** U.S. PATENT DOCUMENTS CLASS SUBCLASS FILING DATE DATE NAME \*EXAMINER **DOCUMENT NUMBER** INITIAL IF APPROPRIATE FA 5 6 8 3 01/28/86 Sunshine, et al. 514 264 12/12/83 5 514 282 02/11/83 FB 4 6 9 9 3 7 02/11/86 Baker, et al. 514 282 12/18/84 FC 4 5 4 0 0 02/18/86 Arnold 7 514 282 12/18/84 5 2 5 05/06/86 FD 4 8 Arnold FE 4 6 1 9 9 3 4 12/28/86 Sunshine, et al. 514 277 07/08/85 FF 6 9 2 7 09/01/87 514 282 02/03/86 4 9 0 Voss, et al. 12/08/87 FG 8 3 9 7 6 06/13/89 Pahkhania, et al. 424 465 465 08/14/86 0 7 07/04/89 424 FH 4 8 4 9 Elger, et al. FI Sunshine, et al. 570 08/21/89 4 9 7 8 5 4 05/22/90 514 282 FJ 5 1 6 4 3 9 8 12/17/92 Sims ,et al. 514 04/01/91 5 7 03/02/93 514 282 08/16/91 FK 1 9 0 9 4 Riess, et al. 5 FL 0 6 9 08/31/93 Gwaltney, Jr. 424 45 12/19/91 FOREIGN PATENT DOCUMENTS SUBCLASS **TRANSLATION DOCUMENT NUMBER** DATE COUNTRY CLASS YES NO FM 0 0 6 8 8 3 8 06/25/82 EP (A1) A61K 31/485 0 0 8 8 06/25/82 EP (B1) A61K 31/485 FN 6 3 8 031/135 F0 2 0 8 1 6 0 4 05/01/95 Canada A61K FΡ FQ OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) FR FS FT DATE CONSIDERED **EXAMINER** 

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIS	ORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (EV. 7-80) PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO.: 200.1079CON6 SERIAL NO.: Not Yet Known				
	T OF PR	IOR AR	T CITEI	D BY AI	PPLICA	NT				APPLICANT(S): Ronald M. BURCH , et al.					
	(Use sev	veral she	eets if n	ecessar	y)				1 1	FILING DATE: Not Yet	ILING DATE: Not Yet Known GROUP: Not Yet Known				
U.S. PATENT DOCU										CUMENTS					
EXAMINER NITIAL		DOCU	IMENT	NUMBE	R				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRI		
	GA	5	4	0	9	9	4	4	04/25/95	Black, et al.	514	359	03/12/93		
	GB	5_	4	3	6	2	6	5	06/25/95	Black, et al.	514	420	11/12/93		
	GC	5	5	1	0	3	6_	8	04/23/96	Lau, et al.	514	419	05/22/95		
	GD	5	5	2	1	2	1	3	05/28/96	Prasit, et al.	514	443	08/29/94		
	GE	5_	5	5	0	1	4	2	08/27/96	Ducharme et al.	514	365	05/08/95		
	GF	5	5	5	2	4	2_	2	09/03/96	Gauthier, et al.	514	368	01/11/95		
	GG	5	6	0	4	2	5	3_	02/18/97	Lau, et al.	514	415	05/22/95		
	GH	5	6	3	9	7	8	0_	06/17/97	Lau, et al.	514	419	05/22/95		
<u> </u>		•	-					FOI	REIGN PATENT D	OCUMENTS					
	DOCUMENT NUMBER DATE									COUNTRY	CLASS	SUBCLASS	TRANSLATI	ON	
													YES	NO	
	GI													-	
	GJ	<u> </u>			ļ	<u> </u>		ļ	<u> </u>						
	GK						<u> </u>	ļ					<u> </u>	_	
	GL						<u> </u>		<u> </u>				-	-	
	GM														
						OTHER	RPRIOR	ART (Ir	ncluding Author, 1	Title, Date, Pertinent Pag	es, Etc.)				
	GN	Anti	i-inflamı	matory l	Drugs ar	nd Their	Mechar	nism of	Action J.R. Vane,	et al. Inflamm. Ress. 47	, Supplement 2 (19	998).			
	GO									<del>_</del>			_	<del>.</del>	
	GP										-				
	GQ														
	GR							_							
EXAMINER										DATE CONSIDERED					

FORM PTO-1449 (REV. 7-80)					-			OF COMMERCE EMARK OFFICE	ATTY. DOCKET NO.: 200.1079CON6		SERIAL NO.: No	t Yet Known		
ι	IST OF PF	RIOR ART	CITED BY	APPLIC <i>i</i>	ANT				APPLICANT(S): Ronal	d M. BURCH, et a	l.			
	(Use se	everal shee	ts if necess	ary)					FILING DATE: Not Yet	Known	GROUP: Not Yet	Known		
							UMENTS	_						
*EXAMINER INITIAL		DOCUM	ENT NUMB	ER				DATE	NAME	CLASS	SUBCLASS	SUBCLASS FILING DATE IF APPROPRIATE		
				<u> </u>	ļ	<u> </u>				1				
								11						
	HD			-	ļ					ļ				
	HE			_										
	HF						_							
	HG		_	-										
	нн		_	-	ļ									
	HI			-						_				
	HJ		_	-			-							
	НК				L	]								
FOREIGN								REIGN PATENT D	DCUMENTS T		1	ı		
		DOCUM	ENT NUME	ER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	V I	
												YES	NO	
	HL													
	нм													
	HN													
	но													
	НР										<u></u>			
<u> </u>	<b>T</b>	,			OTHER	PRIOR .	ART (Inc	cluding Author, Ti	tle, Date, Pertinent Pages	, Etc.)				
	но	Rorarius	s et al., "No	n-Steroid	lal Anti-l	nflamm	atory D	rugs for PostOper	ative Pain Relief," Curr. O	pin. In Anaesthes	iology, 7, 358-362).	(1994)		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	HR		et al. "Phar . Forsch./D						Disclotenac-Codeine Pho	sphate Combinatio	on Following Oral and	l Rectal Administi	ation,"	
	нѕ	Merck I	ndex, Twelf	th Editio	n, Merc	k & Co.	Publish	ers, page 1194. (	1996)					
	нт		in and Gillm ble 22-1, p.			tical Ba	sis of T	herapeutics, "Cha	pter 22: Opioid Analgesics	s and Antagonists	", MacMillan Publishi	ng Co., Inc., pp-4	94-497,	
EXAMINER								-	DATE CONSIDERED		-			
*EXAMINER: Initia	al if referen	ce conside	red whethe	r or not	citation	is in cor	nforman	ce with MPFP 60	9: Draw line through citat	ion if not in confe	rmance and not coos	idered Include s	ony of this	

form with next communication to applicant.